株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鉄欠乏性貧血:パイプライン分析

Iron Deficiency Anemia - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 213042
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
鉄欠乏性貧血:パイプライン分析 Iron Deficiency Anemia - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 68 Pages
概要

貧血とは体内で健全な赤血球が不足している状態をいいます。鉄分は赤血球の生産を助けますが、体内に鉄分が不足すると、生産される赤血球が少なくなるか、あるいは大きさが小さすぎるものとなります。これが鉄欠乏性貧血と呼ばれるものです。苛立ち感や頭痛、集中力や思考力の問題など症状があり、サプリメントや鉄分を多く含む食品の摂取などの治療法があります。

当レポートでは、世界における鉄欠乏性貧血治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

鉄欠乏性貧血の概要

治療薬の開発

  • 鉄欠乏性貧血向けパイプライン製品:概要
  • 鉄欠乏性貧血向けパイプライン製品:比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Panion & Bf Biotech Inc
  • Rockwell Medical, Inc.
  • Vifor Pharma AG

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ferric carboxymaltose
  • ferric citrate
  • ferric maltol
  • ferric pyrophosphate citrate
  • NSC-8679
  • Proteins to Activate Erythroferrone for Iron Deficiency Anemia
  • VIT-91

最新パイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8253IDB

Summary

Global Markets Direct's, 'Iron Deficiency Anemia - Pipeline Review, H2 2016', provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
  • The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects
  • The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Iron Deficiency Anemia Overview
  • Therapeutics Development
    • Pipeline Products for Iron Deficiency Anemia - Overview
    • Pipeline Products for Iron Deficiency Anemia - Comparative Analysis
  • Iron Deficiency Anemia - Therapeutics under Development by Companies
  • Iron Deficiency Anemia - Therapeutics under Investigation by Universities/Institutes
  • Iron Deficiency Anemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Iron Deficiency Anemia - Products under Development by Companies
  • Iron Deficiency Anemia - Products under Investigation by Universities/Institutes
  • Iron Deficiency Anemia - Companies Involved in Therapeutics Development
    • Galenica Ltd.
    • Johnson & Johnson
    • Novartis AG
    • Panion & Bf Biotech Inc
    • Pieris Pharmaceuticals, Inc.
    • Rockwell Medical, Inc.
  • Iron Deficiency Anemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CSJ-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Repalce Iron for Iron Deficiency Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric carboxymaltose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric pyrophosphate citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-42905343 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSC-8679 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRS-080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Iron Deficiency Anemia - Dormant Projects
  • Iron Deficiency Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 28, 2016: Rockwell Medical Announces Triferic Presentation "Overcoming Functional Iron Deficiency in Your Hemodialysis Patients" at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston
      • Mar 29, 2016: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease
      • Mar 21, 2016: China FDA Accepts Rockwell Medical's Triferic Drug Submission for Commercialization in China
      • Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia
      • Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA
      • Dec 01, 2015: Rockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference
      • Nov 30, 2015: Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement
      • Oct 28, 2015: Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology Meeting November 2015
      • Oct 06, 2015: Rockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology Clinical Meeting November 2015
      • Sep 09, 2015: Rockwell Medical Announces the U.S. Commercial Launch of Triferic
      • Aug 31, 2015: A meta-analysis on individual-patient data reports that Ferinject treatment of iron deficiency in patients with systolic chronic heart failure is associated with reduced rates of cardiovascular hospitalisations and cardiovascular deaths
      • Jul 15, 2015: Rockwell Medical Announces Triferic Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation
      • Jul 13, 2015: Rockwell Medical Announces Triferic ESA-Sparing PRIME Study Published in Kidney International
      • May 12, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK
      • May 05, 2015: Rockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Iron Deficiency Anemia, H2 2016
  • Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Iron Deficiency Anemia - Pipeline by Galenica Ltd., H2 2016
  • Iron Deficiency Anemia - Pipeline by Johnson & Johnson, H2 2016
  • Iron Deficiency Anemia - Pipeline by Novartis AG, H2 2016
  • Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H2 2016
  • Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals, Inc., H2 2016
  • Iron Deficiency Anemia - Pipeline by Rockwell Medical, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Iron Deficiency Anemia - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Iron Deficiency Anemia, H2 2016
  • Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top